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Background: Colorectal cancer (CRC) is one of the most commonly occurring neoplasms and a leading cause of
cancer death worldwide, and new preventive strategies are needed to lower the burden of this disease.
Eicosapentaenoic acid (EPA), the omega-3 polyunsaturated fatty acid that is widely used in the treatment of
hyperlipidemia and prevention of cardiovascular disease, has recently been suggested to have a suppressive effect
on tumorigenesis and cancer cell growth. In CRC chemoprevention trials, in general, the incidence of polyps or of
the cancer itself is set as the study endpoint. Although the incidence rate of CRC would be the most reliable
endpoint, use of this endpoint would be unsuitable for chemoprevention trials, because of the relatively low
occurrence rate of CRC in the general population and the long-term observation period that it would necessitate.
Moreover, there is an ethical problem in conducting long-term trials to determine whether a test drug might be
effective or harmful. Aberrant crypt foci (ACF), defined as lesions containing crypts that are larger in diameter and
stain more darkly with methylene blue than normal crypts, are considered as a reliable surrogate biomarker of CRC.
Thus, we devised a prospective randomized controlled trial as a preliminary study prior to a CRC chemoprevention
trial to evaluate the chemopreventive effect of EPA against colorectal ACF formation and the safety of this drug, in
patients scheduled for polypectomy.
Methods: This study is a multicenter, double-blind, placebo-controlled, randomized controlled trial to be
conducted in patients with both colorectal ACF and colorectal polyps scheduled for polypectomy. Eligible patients
shall be recruited for the study and the number of ACF in the rectum counted at the baseline colonoscopy. Then,
the participants shall be allocated randomly to either one of two groups, the EPA group and the placebo group.
Patients in the EPA group shall receive oral 900-mg EPA capsules thrice daily (total daily dose, 2.7 g per day), and
those in the placebo group shall receive oral placebo capsules thrice daily. After one month’s treatment with
EPA/placebo, colonoscopic examination and polypectomy will be performed to evaluate the formation of ACF, and
the cell-proliferative activity and cell-apoptotic activity in normal colorectal mucosa and colorectal polyps.
Discussion: This is the first study proposed to explore the effect of EPA against colorectal ACF formation
in humans.
This trial has been registered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry
as UMIN000008172.* Correspondence: nakajima-tky@umin.ac.jp
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Colorectal cancer (CRC) is amongst the most commonly
encountered neoplasms worldwide [1], and both its
prevalence and mortality have been increasing [2]. Re-
moval of colorectal polyps has been to shown to reduce
the risk of future development of colorectal cancer and
advanced adenoma [3,4] and to thereby prevent colorec-
tal cancer death [5]. On the other hand, patients with
polyps (adenomas and/or hyperplastic polyps) also con-
stitute a high-risk group for the development of meta-
chronous colorectal polyps and/or CRC [6]. Therefore, a
paradigm shift from surveillance for early detection of
cancer or adenomas and polypectomy to new strategies
for prevention, including chemoprevention, is needed to
lower the burden of this disease. Several large epidemio-
logic and/or clinical studies have evaluated the possible
effects of more than 200 agents, including fiber, calcium,
and non-steroidal anti-inflammatory drugs (NSAIDs),
including aspirin and selective cyclooxygenase-2 (COX-
2) inhibitors, in protecting against CRC development
[7]. Our group previously reported that sulindac, a
NSAID, had the effect of suppressing the development
of sporadic colorectal adenoma [8]. Until date, NSAIDs,
especially COX-2 inhibitors, administered either alone
or in combination with other agents, have shown the most
promise for CRC risk reduction [4], although reports have
revealed an increased risk of serious cardiovascular events
associated with the use of COX-2 inhibitors [9,10]. In light
of the adverse cardiovascular effects of COX-2 inhibitors
and the lack of demonstrable efficacy of the other agents
that had initially shown promise in this setting, novel drugs
that would be both safe and effective for CRC prevention
need to be developed. CRC is known to be associated with
lifestyle-related diseases, such as hyperlipidemia, diabetes
mellitus and obesity [11-14], therefore, we considered that
these conditions might represent potential new targets for
CRC chemoprevention.
Eicosapentaenoic acid (EPA) is an omega-3 polyunsatur-
ated fatty acid (PUFA) that has long been used widely for
primary and also secondary prevention of cardiovascular
diseases [15]. EPA impacts the biological functions of adi-
pocytes via two distinct mechanisms; the first, via tran-
scriptional activation of lipogenic and adipogenic genes by
binding to nuclear receptors such as Peroxisome Prolifera-
tor Activator Receptors (PPARs),[16] and the second, via
direct competition with arachidonic acid (AA) incorpor-
ation into membrane phospholipids and subsequent con-
version to eicosanoids, including prostaglandins (PGs). [17]
Recent reports have indicated a lower incidence of colon,
breast and prostate cancers in many human populations,
associated with a high dietary consumption of omega-3
PUFAs. Multiple reports using a variety of rodent models
of early-stage colorectal carcinogenesis, including
azoxymethane- and dimethylhydrazine-induced colorectaltumorigenesis (using aberrant crypt foci (ACF) or colonic
tumors as the primary endpoint), as well as the ApcMin/+
mouse model of familial adenomatous polyposis (FAP),
have demonstrated the efficacy of the free fatty acid (FFA)
form of a combination of EPA plus docosahexaenoic acid
(DHA) (as fish oil substituted for the base fat source in
chow).[18] In humans, a phase-III randomized placebo-
controlled trial of EPA-FFA 2 g daily for 6 months was per-
formed in 55 patients with FAP undergoing sigmoido-
scopic surveillance of a rectal stump after total colrectomy.
[19] Patients in the EPA-FFA arm had a significantly lower
(by 22.4%) number of lower rectal polyps and a 29.8% de-
crease in the sum of the polyp diameters in the tattooed
area of the rectum as compared with the placebo group.
Importantly, daily administration of EPA-FFA 2 g was safe
and well-tolerated. [19] NSAIDs chemoprevention trial set
in past, first conducted to FAP patients, then applied to
sporadic colorectal adenoma/cancer. Thus, much evidence
suggests that EPA might be a candidate agent for CRC che-
moprevention. In CRC chemoprevention trials, in general,
the incidence of polyps or of the cancer itself is set as the
study endpoint. Although the incidence rate of CRC would
be the most reliable endpoint, use of this endpoint would
be unsuitable for chemoprevention trials, because of the
relatively low occurrence rate of CRC in the general popu-
lation [20] and the long-term observation period that it
would necessitate. Moreover, there is an ethical problem in
conducting a long-term trial to determine whether a test
drug may be effective or harmful.
Aberrant crypt foci (ACF), defined as lesions contain-
ing crypts that are larger in diameter and stain more
darkly with methylene blue than normal crypts,[21-24]
are considered as a reliable surrogate biomarker of CRC.
[25] We previously reported the usefulness of ACF as a
biological marker of CRC, [26,27] and carried out a che-
moprevention trial for colorectal ACF. [28,29] Chemo-
prevention trials with colorectal ACF set as the primary
endpoint may have some advantages. First, a long-term
observation period is not needed to evaluate the drug ef-
fect. Our group reported the n.[29] Long-term trials
need much effort and may expose the study participants
to an increased risk of development of carcinoma. Sec-
ond, ACF can be estimated quantitatively. Thus, we
devised a prospective randomized controlled trial to
evaluate the chemopreventive effect of EPA against the
formation of colorectal ACF as a preliminary study prior
to CRC chemoprevention trials.
This is the first clinical trial of EPA as a chemopreven-
tive agent against colorectal ACF in humans.
Methods/design
Study design and setting
This study is designed as a multicenter, double-blind,
placebo-controlled, randomized controlled trial to be
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conducted at the Division of Gastroenterology, Yoko-
hama City University Hospital, and its affiliate hospital,
Chigasaki Municipal Hospital and Yokohama Rosai Hos-
pital. The coordinating office shall be at the Yokohama
City University Hospital, and the registration, rando-
mized allocation and data collection shall be conducted
at this site.
Ethical considerations and registration
The study protocol is in compliance with the Declar-
ation of Helsinki [30] and the Ethics Guidelines for Clin-
ical Research published by the Ministry of Health,
Labour, and Welfare, Japan [31]. We obtained approval
for this study from the Ethics committee of Yokohama
City University Hospital on May 10, 2012. The protocol
and informed consent forms were approved by the insti-
tutional ethics committee at each of the participating
institutions. This trial has been registered in the Univer-
sity hospital Medical Information Network (UMIN)
Clinical Trials Registry as UMIN000008172. Written
informed consent for participation in the study will be
obtained from all the participating patients. The trial
results will be reported in conformity with the Consoli-
dated Standards of Reporting Trials (CONSORT) 2010
guidelines [32].
Eligibility criteria
Patients with both colorectal ACF and resectable polyps
will be recruited for the study.
The proposed inclusion criteria are as follows:
1) Age 40 to 80 years as on the date of informed
consent.
2) Willingness to provide written informed consent.
The proposed exclusion criteria are as follows:
1) History of regular use of omega-3 PUFA
supplements.
2) History of regular use (defined as at least once per
week) of NSAIDs and/or aspirin.
3) History of heart failure, renal failure, liver cirrhosis
or chronic hepatic failure.
4) History of familial adenomatous polyposis.
5) History of hereditary non-polyposis colorectal cancer.
6) History of inflammatory bowel disease.
7) Pregnancy or possibility of pregnancy.
8) Patients judged as being inappropriate candidates for
the trial by the investigators.
Intervention
All eligible patients will be allocated randomly to one of
two groups, the EPA group and the placebo group. Theendoscopists, doctors at the follow-up outpatient clinics,
and patients will be blinded to the allocation. Patients in
the EPA group shall receive oral 900-mg EPA capsules
thrice daily (total daily dose, 2.7 g), and those in the pla-
cebo group shall receive oral placebo capsules thrice a day.
At the end of 1 month of administration of EPA/placebo,
polypectomy will be performed, and the changes in the
number of ACF and in the mucosa will be evaluated.
Outcome measurements
The primary endpoint shall be the change in the number
of colorectal ACF after 1-months’s intervention. The
endoscopic examinations and polypectomies will be per-
formed using Olympus colonoscopes (model H260AZI).
Bowel preparation prior to the colonoscopic procedures
will be as described [33,34]. At the time of the first col-
onoscopy, the endoscope shall be inserted into the
cecum, and the entire colorectum will be carefully
observed as the endoscope is pulled back. If any polyps
are detected, biopsy will be performed. Furthermore, co-
lonic epithelial samples will be obtained. The number of
rectal ACF will be counted with a magnifying endo-
scope, as described [25,33]. At the end of 1 month of ad-
ministration of EPA/placebo, the same endoscopists will
perform the polypectomy and counting of the ACF. All
procedures will be recorded on DVD, and all the ACF
will be photographed. The number of ACF in each pa-
tient will first be counted by the operators during the
performance of the colonoscopy. To further ensure val-
idity, the number of ACF will be counted again through
observation of the recorded DVD by 3 blinded expert
endoscopists (H.T, H.E, and E.S). If these expert endos-
copists judge the colonoscopic examination as having
been inadequate in any case, that case will be excluded.
The secondary outcomes shall be (1) the drug safety;
adverse events (AEs) will be graded according to the Na-
tional Cancer Institute Common Toxicity Criteria for
Adverse Events (NCI-CTCAE), version 4.0. All study
participants shall be provided with a study diary in order
to record the daily dosage of the study treatment and
the AEs. Patients developing grade 3 or more severe ad-
verse events will be withdrawn from the study at that
point; (2) Mucosal fatty acid analysis: Homogenization,
extraction and derivatization of the rectal mucosa and
polyp fatty acids (EPA, DHA, docosapentaenoic acid
(DPA), AA, linolenic acid, linoleic acid, palmitic acid,
stearic acid, etc.) shall be performed as described [35].
Fatty acid content shall be determined by gas chroma-
tography–mass spectrometry and expressed as the per-
centage of the total fatty acid content [36,37]. (3) Effects
of EPA on the cell-proliferative and apoptotic activities
in the rectal epithelium and polyps: Colonic epithelial
samples will be obtained from the same trial patients by
biopsy at the time of the first colonoscopy and
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ated by staining for the proliferative cell nuclear antigen
(PCNA) and estimation of the Ki-67 labeling indices,
and the cell-apoptotic activity by the terminal deoxynu-
cleotidyl transferase-mediated dUTP-biotin nick-end la-
beling (TUNEL) method. (4) Laboratory data (HDL
cholesterol, LDL cholesterol, triglycerides, fatty acid frac-
tions, fasting blood glucose, fasting blood insulin,
HbA1c, blood urea nitrogen (BUN), creatinine); (5)
physical examination findings (body weight, body mass
index (BMI)). EPA is widely used as an anti-
hyperlipidemic drug that improves the plasma lipid pro-
file. The effect of EPA on the plasma lipid profile will be
evaluated by comparing these parameters measured at
the baseline with those measured after 1 month of treat-
ment in the EPA group and placebo group. All partici-
pants will undergo a physical examination and
laboratory tests at the time of the baseline endoscopic
examination and polypectomy.
Randomization
The investigator shall convey the patient’s details to the
central registration center via fax. After an eligibility
check, the patients will be randomly assigned to receive
EPA or placebo at the central registration center by a
computer program using a minimization method, with
stratification by age, gender, BMI, and institution. Thus,
the patient assignment will be concealed from the inves-
tigator. The randomization center will allocate a num-
bered treatment pack to each patient, which will contain
all the drugs or placebos needed to complete a course of
the trial treatment for that patient.
Drug supply
Enteric-coated EPA capsules (Ethyl icosapentate granular
capsuleW) and the placebo capsules (capric, caprylic and
lauric acid medium-chain triglycerides) will be pur-
chased from Nipro Pharma Corporation Co., Ltd, Osaka,
Japan. All trial drugs will be packaged identically and
identified only by number. Subjects will be instructed to
take one package of the trial drug after every meal each
day. Compliance will be monitored by counting the
empty drug packages returned by the patients at
polypectomy.
Sample size estimation
In the chemoprevention trial conducted in FAP patients,
the NSAID sulindac and selective cyclooxygenase-2
(COX-2) inhibitor celecoxib reduced polyposis of the
retained rectum after colectomy with ileorectal anasta-
mosis (IRA). As previously noted, EPA has a suppressive
effect for polyp formation and proliferation of FAP [19].
From these reports, we estimated that NSAIDs and EPAmay have equivalent effect on suppression of polyp for-
mation and proliferation.
Based on the target in the NSAIDs chemoprevention
study for ACF, Takayama et al. reported that sulindac ad-
ministration at 300 mg/d for 2 months to post-
polypectomy patients suppressed ACF formation, de-
creasing the number of ACF from 7.70 ± 4.04 (baseline)
to 4.00 ± 2.95 (at 2 months, p < 0.001) [33]. Presuming
EPA and sulindac may have equivalent effect in suppres-
sing ACF formation, to detect the reduction in the num-
ber of ACFs in the EPA group using the Mann–Whitney
U test with a two-sided significance level of 5% and a
power of 80%, it was estimated that a sample size of 12
patients per group would be necessary. Assuming a 10%
dropout rate, we propose to recruit 15 patients per
group, that is, a total of 30 patients.
Statistical analysis
The number of ACFs in each group, the primary end-
point, will be compared between the EPA group and the
placebo group by the Mann–Whitney U test. The safety,
one of the secondary endpoints, will be compared by the
chi-square test. The remaining results in the two groups
will be compared by the Mann–Whitney U test or Stu-
dent’s t test. A P values of < 0.05 will be regarded as indi-
cative of significance. The analysis will be performed
using SPSS, version 17.0 (SPSS Inc., Chicago, Il.).
Trial Steering Committee and Data Monitoring Committee
The Trial Steering Committee and Data Monitoring
Committee shall be located at the Department of
Gastroenterology, Kanto Medical Center, NTT East. The
committee shall consist of three people: Nobuyuki
Matsuhashi, M.D., Toshio Fujisawa, M.D., and Jun
Hamanaka, M.D. The Management Team will monitor
the trial progress status and data by face-to-face and/or
telephonic contact with each of the sites every month.
Study flow
A flow chart of the study is shown in Figure 1.
Discussion
This is the first study proposed to explore the effect of
EPA against colorectal ACF formation. Knowledge of the
mechanisms underlying the anti-neoplastic activity of
EPA remains nebulous. Current understanding of the
mechanistic aspects of the anticancer activity of EPA has
been reviewed in detail in published reviews [38-41]. In
general, the major mechanisms proposed to underlie the
anti-neoplastic activities of EPA; (1) modulation of COX
activity, (2) alteration of the membrane dynamics and
cell surface receptor function, and (3) increased cellular
oxidative stress. However, the in vivo relevance of each
of the above putative mechanisms and their relative
Both with colorectal ACF and resectable polyps :n= 
Exclude if : meets exclusion criteria
Reasons:
Total subjects enrolled : n=30
EPA group : n=15 Placebo group : n=15
Randomized allocation
Taking EPA 2.7 g daily
1-month follow-up colonoscopy (polypectomy)
Taking placebo capsules daily
Lost to follow up: n=
Discontinue intervention: n=
Lost to follow up: n=
Discontinue intervention: n=
Analyzed: n =
Exclude analysis: n =
Reasons: 
Analyzed: n =
Exclude analysis: n =
Reasons: 
Figure 1 Study Flow.
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unclear. Several in-vitro studies have explored the anti-
neoplastic activity of omega-3 PUFAs against human
CRC cells, and EPA treatment has been shown to reduce
cellular proliferative activity and increase cellular apop-
totic activity [42-45]. EPA can act as an alternative sub-
strate for COX-2, instead of AA, leading to a reduction
in the formation of the pro-tumorigenic ‘2-series’ PGs
(e.g., PGE2) in favor of the ‘three-series’ PGs (e.g., PGE3)
in several cell types, including CRC cells [46-48]. Fur-
thermore, incorporation of EPA into the cell phospho-
lipid membrane alters the fluidity, structure, and/or
function of the lipid rafts or calveolae [49], which are
sphingolipid- and cholesterol-rich microdomains that
float freely in the cell membrane. The localization of cell
surface receptors, such as epidermal growth factor re-
ceptor (EGFR) [50], in lipid rafts is believed to be crucial
for downstream receptor signaling, controlling prolifera-
tion and apoptosis [51,52]. Furthermore, EPA may exert
an antineoplastic effect through alteration of the cellular
redox state and of the oxidative stress exposure of the
cells. PUFAs are highly peroxidizable, which generates
reactive oxygen species (ROS), such as superoxide radi-
cals. Many tumor cells display altered cellular pathways
for the handling of ROS, including depletion of the
major intracellular antioxidant, glutathione. Subsequent
elevation of the intracellular ROS levels by EPA has been
hypothesized to induce cancer cell apoptosis [53].
This trial may have the following limitations. First,
ACF are considered as a reliable surrogate biomarker of
CRC, [21] although their biological significance stillremains controversial. In CRC chemoprevention trials,
in general, the incidence of polyps or of the cancer itself
is set as the study endpoint. Although the incidence rate
of CRC would be the most reliable endpoint, use of this
endpoint would be unsuitable for chemoprevention
trials, because of the relatively low occurrence rate of
CRC in the general population [18] and the long-term
observation period that it would necessitate. We previ-
ously reported the usefulness of ACF as a biological
marker of CRC [26,27] and carried out a chemopreven-
tion trial for colorectal ACF [28,29]. Thus, we devised a
trial using this endpoint (ACF) to evaluate the chemo-
preventive effect of EPA. Second, we do not propose to
conduct a dose–response study in respect of the effect
of EPA on ACF formation. Until now, trials of EPA for
cancer prevention and adjuvant treatment have been
conducted using EPA at doses of 1000 – 4000 mg per
day. In Japan, the EPA drug product specification is
0.9 g, and 2.7 g of EPA has been commonly used and
very well tolerated. Therefore, we planned to conduct
this trial using 2.7 g of EPA per day. Third, an interven-
tion period of 1 month may be too short to allow reli-
able detection of differences between the groups.
However, we showed in a previous study that oral ad-
ministration of metformin for 1 month suppressed the
formation of colorectal ACF in humans [29]. If the inter-
vention agents had a chemopreventive effect, an inter-
vention period of 1 month would be sufficient to
evaluate the changes in the number of ACF.
We previously conducted a short-term chemopreven-
tion trial of metformin for colorectal ACF, and showed
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ACF. Thereafter, we are conducting a long-term metfor-
min chemoprevention trial for colorectal polyps, the trial
registered in the UMIN Clinical Trials Registry as
UMIN000006254 [34]. We propose to repeat the same
step for the chemoprevention trial using EPA.
If EPA were found to be effective for the prevention of
CRC, the impact would be extremely large. We consider
it of interest, therefore, to determine whether EPA might
suppress the formation of human colorectal ACFs.
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